Does the media favor MDXG or AGIO?

In the previous week, Agios Pharmaceuticals had 25 more articles in the media than MiMedx Group. MarketBeat recorded 30 mentions for Agios Pharmaceuticals and 5 mentions for MiMedx Group. Agios Pharmaceuticals' average media sentiment score of 0.56 beat MiMedx Group's score of 0.26 indicating that Agios Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MiMedx Group 2 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Agios Pharmaceuticals 5 Very Positive mention(s) 5 Positive mention(s) 10 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive

Which has preferable valuation & earnings, MDXG or VCEL?

MiMedx Group has higher revenue and earnings than Vericel. MiMedx Group is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MiMedx Group $418.63M 1.12 $48.58M -$0.13 N/A Vericel $276.26M 8.43 $16.52M $0.47 96.77

Is MDXG or VCEL more profitable?

Vericel has a net margin of 7.91% compared to MiMedx Group's net margin of -6.32%. Vericel's return on equity of 6.91% beat MiMedx Group's return on equity. Company Net Margins Return on Equity Return on Assets MiMedx Group -6.32% 2.39% 1.85% Vericel 7.91% 6.91% 5.02%

Does the media favor MDXG or VCEL?

In the previous week, MiMedx Group had 3 more articles in the media than Vericel. MarketBeat recorded 5 mentions for MiMedx Group and 2 mentions for Vericel. Vericel's average media sentiment score of 0.56 beat MiMedx Group's score of 0.26 indicating that Vericel is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MiMedx Group 2 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Vericel 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, XNCR or MDXG?

MiMedx Group has higher revenue and earnings than Xencor. MiMedx Group is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Xencor $125.58M 20.74 -$91.92M -$2.17 N/A MiMedx Group $418.63M 1.12 $48.58M -$0.13 N/A

Is XNCR or MDXG more profitable?

MiMedx Group has a net margin of -6.32% compared to Xencor's net margin of -155.59%. MiMedx Group's return on equity of 2.39% beat Xencor's return on equity. Company Net Margins Return on Equity Return on Assets Xencor -155.59% -28.66% -20.38% MiMedx Group -6.32% 2.39% 1.85%

Does the media prefer XNCR or MDXG?

In the previous week, Xencor had 2 more articles in the media than MiMedx Group. MarketBeat recorded 7 mentions for Xencor and 5 mentions for MiMedx Group. Xencor's average media sentiment score of 0.74 beat MiMedx Group's score of 0.26 indicating that Xencor is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xencor 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MiMedx Group 2 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor MDXG or RXRX?

In the previous week, Recursion Pharmaceuticals had 13 more articles in the media than MiMedx Group. MarketBeat recorded 18 mentions for Recursion Pharmaceuticals and 5 mentions for MiMedx Group. MiMedx Group's average media sentiment score of 0.26 beat Recursion Pharmaceuticals' score of 0.08 indicating that MiMedx Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MiMedx Group 2 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Recursion Pharmaceuticals 2 Very Positive mention(s) 4 Positive mention(s) 8 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings & valuation, PGEN or MDXG?

MiMedx Group has higher revenue and earnings than Precigen. MiMedx Group is trading at a lower price-to-earnings ratio than Precigen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Precigen $9.68M 185.99 -$250.64M -$1.04 N/A MiMedx Group $418.63M 1.12 $48.58M -$0.13 N/A

Is PGEN or MDXG more profitable?

MiMedx Group has a net margin of -6.32% compared to Precigen's net margin of -183.98%. Precigen's return on equity of 423.75% beat MiMedx Group's return on equity. Company Net Margins Return on Equity Return on Assets Precigen -183.98% 423.75% 84.39% MiMedx Group -6.32% 2.39% 1.85%

Does the media refer more to PGEN or MDXG?

In the previous week, Precigen had 10 more articles in the media than MiMedx Group. MarketBeat recorded 15 mentions for Precigen and 5 mentions for MiMedx Group. Precigen's average media sentiment score of 0.54 beat MiMedx Group's score of 0.26 indicating that Precigen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Precigen 4 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive MiMedx Group 2 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

MiMedx Group (MDXG) Competitors

$3.28 +0.08 (+2.50%)

Closing price 04:00 PM Eastern

Extended Trading

$3.38 +0.11 (+3.20%)

As of 07:30 PM Eastern

Compare

MDXG vs. AGIO, VCEL, XNCR, RXRX, and PGEN

Should you buy MiMedx Group stock or one of its competitors? MiMedx Group's main competitors and comparable companies include Agios Pharmaceuticals (AGIO), Vericel (VCEL), Xencor (XNCR), Recursion Pharmaceuticals (RXRX), and Precigen (PGEN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does MiMedx Group compare to Agios Pharmaceuticals?

MiMedx Group (NASDAQ:MDXG) and Agios Pharmaceuticals (NASDAQ:AGIO) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, risk, earnings, valuation, media sentiment and analyst recommendations.

MiMedx Group currently has a consensus price target of $8.14, suggesting a potential upside of 154.46%. Agios Pharmaceuticals has a consensus price target of $41.50, suggesting a potential upside of 32.25%. Given MiMedx Group's stronger consensus rating and higher probable upside, analysts plainly believe MiMedx Group is more favorable than Agios Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiMedx Group	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Agios Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.60

MiMedx Group has a net margin of -6.32% compared to Agios Pharmaceuticals' net margin of -418.24%. MiMedx Group's return on equity of 2.39% beat Agios Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiMedx Group	-6.32%	2.39%	1.85%
Agios Pharmaceuticals	-418.24%	-35.67%	-33.06%

MiMedx Group has higher revenue and earnings than Agios Pharmaceuticals. MiMedx Group is trading at a lower price-to-earnings ratio than Agios Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiMedx Group	$418.63M	1.12	$48.58M	-$0.13	N/A
Agios Pharmaceuticals	$54.03M	34.67	-$412.78M	-$7.01	N/A

MiMedx Group has a beta of 1.17, indicating that its stock price is 17% more volatile than the broader market. Comparatively, Agios Pharmaceuticals has a beta of 0.66, indicating that its stock price is 34% less volatile than the broader market.

In the previous week, Agios Pharmaceuticals had 25 more articles in the media than MiMedx Group. MarketBeat recorded 30 mentions for Agios Pharmaceuticals and 5 mentions for MiMedx Group. Agios Pharmaceuticals' average media sentiment score of 0.56 beat MiMedx Group's score of 0.26 indicating that Agios Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MiMedx Group	2 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Agios Pharmaceuticals	5 Very Positive mention(s)	5 Positive mention(s)	10 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

79.2% of MiMedx Group shares are held by institutional investors. 2.5% of MiMedx Group shares are held by insiders. Comparatively, 5.4% of Agios Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

MiMedx Group beats Agios Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

How does MiMedx Group compare to Vericel?

MiMedx Group (NASDAQ:MDXG) and Vericel (NASDAQ:VCEL) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, media sentiment, risk, institutional ownership, earnings, dividends and analyst recommendations.

MiMedx Group has higher revenue and earnings than Vericel. MiMedx Group is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiMedx Group	$418.63M	1.12	$48.58M	-$0.13	N/A
Vericel	$276.26M	8.43	$16.52M	$0.47	96.77

Vericel has a net margin of 7.91% compared to MiMedx Group's net margin of -6.32%. Vericel's return on equity of 6.91% beat MiMedx Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiMedx Group	-6.32%	2.39%	1.85%
Vericel	7.91%	6.91%	5.02%

79.2% of MiMedx Group shares are held by institutional investors. 2.5% of MiMedx Group shares are held by company insiders. Comparatively, 7.6% of Vericel shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

MiMedx Group has a beta of 1.17, indicating that its stock price is 17% more volatile than the broader market. Comparatively, Vericel has a beta of 1.08, indicating that its stock price is 8% more volatile than the broader market.

In the previous week, MiMedx Group had 3 more articles in the media than Vericel. MarketBeat recorded 5 mentions for MiMedx Group and 2 mentions for Vericel. Vericel's average media sentiment score of 0.56 beat MiMedx Group's score of 0.26 indicating that Vericel is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MiMedx Group	2 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vericel	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MiMedx Group presently has a consensus target price of $8.14, suggesting a potential upside of 154.46%. Vericel has a consensus target price of $57.20, suggesting a potential upside of 25.77%. Given MiMedx Group's stronger consensus rating and higher possible upside, equities analysts clearly believe MiMedx Group is more favorable than Vericel.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiMedx Group	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Vericel	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

MiMedx Group and Vericel tied by winning 8 of the 16 factors compared between the two stocks.

How does MiMedx Group compare to Xencor?

Xencor (NASDAQ:XNCR) and MiMedx Group (NASDAQ:MDXG) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, media sentiment, dividends, earnings, valuation and risk.

In the previous week, Xencor had 2 more articles in the media than MiMedx Group. MarketBeat recorded 7 mentions for Xencor and 5 mentions for MiMedx Group. Xencor's average media sentiment score of 0.74 beat MiMedx Group's score of 0.26 indicating that Xencor is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xencor	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MiMedx Group	2 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

MiMedx Group has higher revenue and earnings than Xencor. MiMedx Group is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xencor	$125.58M	20.74	-$91.92M	-$2.17	N/A
MiMedx Group	$418.63M	1.12	$48.58M	-$0.13	N/A

79.2% of MiMedx Group shares are owned by institutional investors. 5.1% of Xencor shares are owned by company insiders. Comparatively, 2.5% of MiMedx Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Xencor has a beta of 0.78, meaning that its stock price is 22% less volatile than the broader market. Comparatively, MiMedx Group has a beta of 1.17, meaning that its stock price is 17% more volatile than the broader market.

Xencor currently has a consensus price target of $39.33, indicating a potential upside of 12.28%. MiMedx Group has a consensus price target of $8.14, indicating a potential upside of 154.46%. Given MiMedx Group's stronger consensus rating and higher probable upside, analysts clearly believe MiMedx Group is more favorable than Xencor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xencor	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64
MiMedx Group	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

MiMedx Group has a net margin of -6.32% compared to Xencor's net margin of -155.59%. MiMedx Group's return on equity of 2.39% beat Xencor's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xencor	-155.59%	-28.66%	-20.38%
MiMedx Group	-6.32%	2.39%	1.85%

Summary

MiMedx Group beats Xencor on 10 of the 15 factors compared between the two stocks.

How does MiMedx Group compare to Recursion Pharmaceuticals?

MiMedx Group (NASDAQ:MDXG) and Recursion Pharmaceuticals (NASDAQ:RXRX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, valuation, analyst recommendations, profitability, media sentiment and earnings.

MiMedx Group has higher revenue and earnings than Recursion Pharmaceuticals. MiMedx Group is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiMedx Group	$418.63M	1.12	$48.58M	-$0.13	N/A
Recursion Pharmaceuticals	$74.68M	27.81	-$644.76M	-$1.04	N/A

MiMedx Group has a net margin of -6.32% compared to Recursion Pharmaceuticals' net margin of -697.15%. MiMedx Group's return on equity of 2.39% beat Recursion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiMedx Group	-6.32%	2.39%	1.85%
Recursion Pharmaceuticals	-697.15%	-47.85%	-36.26%

In the previous week, Recursion Pharmaceuticals had 13 more articles in the media than MiMedx Group. MarketBeat recorded 18 mentions for Recursion Pharmaceuticals and 5 mentions for MiMedx Group. MiMedx Group's average media sentiment score of 0.26 beat Recursion Pharmaceuticals' score of 0.08 indicating that MiMedx Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MiMedx Group	2 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Recursion Pharmaceuticals	2 Very Positive mention(s)	4 Positive mention(s)	8 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

MiMedx Group currently has a consensus price target of $8.14, indicating a potential upside of 154.46%. Recursion Pharmaceuticals has a consensus price target of $8.18, indicating a potential upside of 110.82%. Given MiMedx Group's stronger consensus rating and higher possible upside, equities research analysts clearly believe MiMedx Group is more favorable than Recursion Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiMedx Group	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Recursion Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

MiMedx Group has a beta of 1.17, indicating that its share price is 17% more volatile than the broader market. Comparatively, Recursion Pharmaceuticals has a beta of 1.15, indicating that its share price is 15% more volatile than the broader market.

79.2% of MiMedx Group shares are owned by institutional investors. Comparatively, 89.1% of Recursion Pharmaceuticals shares are owned by institutional investors. 2.5% of MiMedx Group shares are owned by company insiders. Comparatively, 6.7% of Recursion Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

MiMedx Group beats Recursion Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does MiMedx Group compare to Precigen?

Precigen (NASDAQ:PGEN) and MiMedx Group (NASDAQ:MDXG) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, dividends, media sentiment, risk, analyst recommendations, valuation and institutional ownership.

In the previous week, Precigen had 10 more articles in the media than MiMedx Group. MarketBeat recorded 15 mentions for Precigen and 5 mentions for MiMedx Group. Precigen's average media sentiment score of 0.54 beat MiMedx Group's score of 0.26 indicating that Precigen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Precigen	4 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
MiMedx Group	2 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Precigen has a beta of 1.01, indicating that its share price is 1% more volatile than the broader market. Comparatively, MiMedx Group has a beta of 1.17, indicating that its share price is 17% more volatile than the broader market.

MiMedx Group has higher revenue and earnings than Precigen. MiMedx Group is trading at a lower price-to-earnings ratio than Precigen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Precigen	$9.68M	185.99	-$250.64M	-$1.04	N/A
MiMedx Group	$418.63M	1.12	$48.58M	-$0.13	N/A

33.5% of Precigen shares are held by institutional investors. Comparatively, 79.2% of MiMedx Group shares are held by institutional investors. 41.4% of Precigen shares are held by company insiders. Comparatively, 2.5% of MiMedx Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Precigen currently has a consensus target price of $13.67, suggesting a potential upside of 170.63%. MiMedx Group has a consensus target price of $8.14, suggesting a potential upside of 154.46%. Given Precigen's higher probable upside, analysts clearly believe Precigen is more favorable than MiMedx Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Precigen	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
MiMedx Group	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

MiMedx Group has a net margin of -6.32% compared to Precigen's net margin of -183.98%. Precigen's return on equity of 423.75% beat MiMedx Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Precigen	-183.98%	423.75%	84.39%
MiMedx Group	-6.32%	2.39%	1.85%

Summary

Precigen and MiMedx Group tied by winning 8 of the 16 factors compared between the two stocks.

Get MiMedx Group News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MDXG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MDXG vs. The Competition

Export

Metric	MiMedx Group	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$466.96M	$4.10B	$7.79B	$11.66B
Dividend Yield	N/A	3.63%	2.48%	4.43%
P/E Ratio	106.67	25.42	35.35	31.50
Price / Sales	1.14	16.43	8.30	5.60
Price / Cash	5.78	26.76	21.67	22.93
Price / Book	2.26	4.21	4.63	3.84
Net Income	$48.58M	-$22.09M	$3.50B	$381.77M
7 Day Performance	-17.38%	-5.61%	-3.93%	-5.42%
1 Month Performance	-27.91%	-11.78%	-7.10%	-9.50%
1 Year Performance	-58.79%	-0.15%	0.78%	-9.25%

MiMedx Group Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MDXG MiMedx Group	2.5952 of 5 stars	$3.28 +2.5%	$8.14 +148.3%	-58.4%	$466.96M	$418.63M	106.67	808
AGIO Agios Pharmaceuticals	3.562 of 5 stars	$37.32 +1.3%	$41.50 +11.2%	-21.6%	$2.23B	$54.03M	N/A	540	Trending News Earnings Report Analyst Revision
VCEL Vericel	2.0599 of 5 stars	$43.56 +1.2%	$57.20 +31.3%	+25.5%	$2.23B	$276.26M	92.57	398	Trending News Earnings Report Gap Up
XNCR Xencor	3.2767 of 5 stars	$29.65 +1.6%	$39.33 +32.7%	+155.7%	$2.22B	$104.97M	N/A	260	News Coverage Earnings Report Analyst Forecast
RXRX Recursion Pharmaceuticals	2.2781 of 5 stars	$4.11 +8.0%	$8.18 +99.3%	-22.4%	$2.20B	$74.68M	N/A	600	Trending News Earnings Report Insider Trade Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MDXG) was last updated on 11/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MiMedx Group (MDXG) Competitors

MDXG vs. AGIO, VCEL, XNCR, RXRX, and PGEN

How does MiMedx Group compare to Agios Pharmaceuticals?

Summary

How does MiMedx Group compare to Vericel?

Summary

How does MiMedx Group compare to Xencor?

Summary

How does MiMedx Group compare to Recursion Pharmaceuticals?

Summary

How does MiMedx Group compare to Precigen?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDXG vs. The Competition

MiMedx Group Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MiMedx Group (MDXG) Competitors

MDXG vs. AGIO, VCEL, XNCR, RXRX, and PGEN

How does MiMedx Group compare to Agios Pharmaceuticals?

Do analysts recommend MDXG or AGIO?

Is MDXG or AGIO more profitable?

Which has higher earnings & valuation, MDXG or AGIO?

Which has more risk and volatility, MDXG or AGIO?

Does the media favor MDXG or AGIO?

Do institutionals & insiders hold more shares of MDXG or AGIO?

Summary

How does MiMedx Group compare to Vericel?

Which has preferable valuation & earnings, MDXG or VCEL?

Is MDXG or VCEL more profitable?

Do institutionals and insiders hold more shares of MDXG or VCEL?

Which has more volatility and risk, MDXG or VCEL?

Does the media favor MDXG or VCEL?

Do analysts recommend MDXG or VCEL?

Summary

How does MiMedx Group compare to Xencor?

Does the media prefer XNCR or MDXG?

Which has higher valuation and earnings, XNCR or MDXG?

Do insiders and institutionals believe in XNCR or MDXG?

Which has more risk & volatility, XNCR or MDXG?

Do analysts recommend XNCR or MDXG?

Is XNCR or MDXG more profitable?

Summary

How does MiMedx Group compare to Recursion Pharmaceuticals?

Which has better valuation & earnings, MDXG or RXRX?

Is MDXG or RXRX more profitable?

Does the media favor MDXG or RXRX?

Do analysts recommend MDXG or RXRX?

Which has more volatility & risk, MDXG or RXRX?

Do institutionals & insiders have more ownership in MDXG or RXRX?

Summary

How does MiMedx Group compare to Precigen?

Does the media refer more to PGEN or MDXG?

Which has more volatility & risk, PGEN or MDXG?

Which has preferable earnings & valuation, PGEN or MDXG?

Do insiders & institutionals have more ownership in PGEN or MDXG?

Do analysts rate PGEN or MDXG?

Is PGEN or MDXG more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDXG vs. The Competition

MiMedx Group Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools